Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12567642 | 0.96 | THRB (0.34) | THRBMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12731125 | 0.91 | THRB (0.36) | THRBMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12154225 | 0.88 | THRB (0.38) | THRBMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13560673 | 0.87 | THRB (0.40) | THRBMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL5961814 | 0.84 | ALDH1A1 (0.33) | MAOBTDP1L3MBTL1 | |
| SCHEMBL15583455 | 0.83 | MAPT (0.39) | THRBSMN1; SMN2MAPTKMT2ATP53 | |
| SCHEMBL5961813 | 0.83 | RXRA (0.36) | THRBMAOB | |
| SCHEMBL13664620 | 0.82 | RXRA (0.37) | THRBMAOBMAPTKMT2AMEN1 | |
| SCHEMBL12567643 | 0.82 | THRB (0.39) | THRBADRB2ADRB1 | |
| SCHEMBL5961817 | 0.81 | KMT2A (0.39) | THRBNPC1MAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168734-B2 | Lateral alpha-substituted acrylate compound and polymer thereof | JNC CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | CHISSO CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | LEF1, AFF1, CNKSR1 | THRB 1814/4885MAOB 3983/4885NPC1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.